HOUSTON--(BUSINESS WIRE)--Stem Cell Innovations, Inc. (OTCBB:SCLL) announced today the issuance of a key patent covering human pluripotent stem cells in the United States. “The patent provides a broad blocking position for the pluripotent cells of interest to Stem Cell Innovations as it covers isolated human primordial germ cell derived pluripotent cells,” said Stem Cell Innovations CEO Dr. James Kelly. “We believe that this is a fundamental patent in human stem cell biology and an important addition to our foundational IP.” The patent was issued in the United States as U.S. Patent No. 7,153,684 and is licensed exclusively to Stem Cell Innovations.
